Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to determine the single dose, relative BA of new SDS-containing formulations of BILR
355 (150 mg and 200 mg capsules and 150 mg tablet), compared to the current SDS tablet
formulation (50 mg tablet)